Anti-Mouse CD29 (Clone KMI6) – Purified in vivo PLATINUM™ Functional Grade

B cell-supportive stromal cell line BMS2

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM^TM antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

KMI6 activity is directed against mouse CD29, also known as integrin beta 1.

Stromal cells are needed for the early steps of B lymphocyte differentiation and proliferation¹. CD29, also known as integrin beta 1², is a 110 kDa protein discovered due to its expression on bone marrow stromal cells, at cell surface areas that interact with undifferentiated lymphoid cells¹. Integrin beta 1 is a member of a family of alpha beta heterodimers that act as cell surface receptors for extracellular matrix proteins³, including collagen, fibronectin, fibrinogen, laminin, VCAM1, and vitronectin among others⁴. CD29 is also involved in sperm-egg fusion. Through these interactions, CD29 regulates and/or promotes cell adhesion, laminin matrix deposition, endothelial cell motility, angiogenesis, osteoblast compaction, the formation of mineralized bone nodules, and cytokinesis.

KMI6 was raised against the B cell-supportive stromal cell line BMS2¹. LOU/MN rats were immunized with BMS2 cells and subsequently spleen cells were fused with murine Sp2/0 for hybridoma generation. Antibody recognition is insensitive to the glycosylation state but is lost when the CD29 protein is reduced for Western blotting². As such, the epitope is likely conformation-dependent. KMI6 was used to identify CD29². KMI6 can enhance cell adhesion of fibronectin to CD4 ^-8^- thymocytes³.

CD29 is present on the plasma membranes of many stromal cells, bone marrow stromal cell line BMS2 in vitro, and a small number of cells in bone marrow cell suspensions from adult mice. CD29 is also expressed in the media layer of the arterial wall. CD29 is expressed in skeletal and cardiac muscles. CD29 is also constitutively expressed by some immature thymocytes. CD29 can be slightly induced on mature thymocytes and peripheral T cells by activation with Con A.

Alpha-1, alpha-2, alpha-3, alpha-4, alpha-5, alpha-6, alpha-7, alpha-8, alpha-9, alpha-10, alpha-11 or alpha-V, collagen, fibronectin, fibrinogen, laminin, VCAM1, and vitronectin among others

1. Jacobsen K, Miyake K, Kincade PW, et al. J Exp Med. 176(4):927-935. 1992.
2. Wu X, Miyake K, Medina KL, et al. Hybridoma. 13(5):409-416. 1994.
3. Wadsworth SA, Chang AC, Hong MJ, et al. J Immunol. 154(5):2125-2133. 1995.
4. https://www.uniprot.org/uniprotkb/P09055/entry